Acer Therapeutics Inc. Securities Litigation

If you purchased a significant amount of shares of Acer Therapeutics Inc. (NASDAQ: ACER), you have certain options. Investors should register for updates.


Lawsuit Overview

Defendant:Acer Therapeutics Inc.
Date Filed:July 1st, 2019
Sector:Health Care
Industry:Major Pharmaceuticals

According to the Complaint, Acer is a pharmaceutical company that purportedly focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Acer's pipeline includes, inter alia, EDSIVO (celiprolol) for the treatment of vEDS in patients with a confirmed type III collagen mutation.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operational and compliance policies. Specifically, the Complaint alleges Defendants made false and/or misleading statements and/or failed to disclose that: (i) Acer lacked sufficient data to support filing EDSIVO's NDA with the FDA for the treatment of vEDS; (ii) the Ong Trial was an inadequate and ill-controlled clinical study by FDA standards, and was comprised of an insufficiently small group size to support EDSIVO's NDA; (iii) consequently, the FDA would likely reject EDSIVO's NDA; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Sign up for free to create a personalized portfolio with tracking and e-mail alerts for Acer Therapeutics Inc.

First Identified Complaint

Tyler Sell, et al. v. Acer Therapeutics Inc., et al.

Date Filed:July 1st, 2019
Class Period Start:September 25th, 2017
Class Period End:June 24th, 2019
First Identified Complaint Filings
#Document TitleFiling Date